AstraZeneca PLC is celebrating its first full year of sales growth since 2009 thanks to stellar performances from its oncology products, notably the lung cancer drug Tagrisso, which is expected to become the group's biggest seller in 2019.
During an upbeat media conference to announce its fourth-quarter earnings, AstraZeneca management unveiled strong sales growth for its big three...








